Carlos Cordon-Cardo

List of Publications by Year in Descending Order

368 papers	53,890 citations	110 h-index	229 g-index
390 ext. papers	59,638 ext. citations	13.7 avg, IF	7.04 L-index

#	Paper	IF	Citations
368	Creating Surveillance Data Infrastructure Using Laboratory Analytics: Leveraging Visiun and Epic Systems to Support COVID-19 Pandemic Response.. *Journal of Pathology Informatics*, **2022**, 13, 2	4.4	
367	MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. *Cancer Letters*, **2022**, 525, 46-54	9.9	2
366	Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence.. *Acta Neuropathologica Communications*, **2022**, 10, 21	7.3	1
365	Food for thought: Eating before saliva collection and interference with SARS-CoV-2 detection.. *Journal of Medical Virology*, **2022**,	19.7	2
364	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.. *Cancer Cell*, **2022**,	24.3	3
363	Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer. *Cancers*, **2022**, 14, 2734	6.6	0
362	Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment. *Blood*, **2021**, 138, 822-822	2.2	1
361	Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. *Heliyon*, **2021**, 7, e08444	3.6	0
360	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. *Cancer Cell*, **2021**, 39, 1442-1444	24.3	25
359	Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019. *Journal of Infectious Diseases*, **2021**, 223, 1842-1854	7	13
358	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. *Modern Pathology*, **2021**, 34, 1456-1467	9.8	59
357	RT-PCR/MALDI-TOF mass spectrometry-based detection of SARS-CoV-2 in saliva specimens. *Journal of Medical Virology*, **2021**, 93, 5481-5486	19.7	10
356	The human leukocyte antigen as a candidate tumor suppressor. *Cancer Cell*, **2021**, 39, 586-589	24.3	1
355	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 301.e17-301.e28	2.8	1
354	Analysis of sex-specific risk factors and clinical outcomes in COVID-19. *Communications Medicine*, **2021**, 1,		6
353	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. *Gastroenterology*, **2021**, 160, 2435-2450.e34	13.3	45
352	Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave. *Nature Communications*, **2021**, 12, 3463	17.4	0

351	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. *Gut*, **2021**,	19.2	8
350	Neutralizing Antibody Responses in COVID-19 Convalescent Sera. *Journal of Infectious Diseases*, **2021**, 223, 47-55	7	40
349	AKI in Hospitalized Patients with COVID-19. *Journal of the American Society of Nephrology: JASN*, **2021**, 32, 151-160	12.7	225
348	Association of SARS-CoV-2 viral load at admission with in-hospital acute kidney injury: A retrospective cohort study. *PLoS ONE*, **2021**, 16, e0247366	3.7	2
347	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. *Cancer Cell*, **2021**, 39, 1028-1030	24.3	81
346	Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. *Human Pathology*, **2021**, 114, 110-119	3.7	8
345	Molecular Profiling of Coronavirus Disease 2019 (COVID-19) Autopsies Uncovers Novel Disease Mechanisms. *American Journal of Pathology*, **2021**, 191, 2064-2071	5.8	1
344	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. *Frontiers in Oncology*, **2021**, 11, 734963	5.3	0
343	The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic. *Academic Pathology*, **2021**, 8, 23742895211006818	1.3	2
342	Screening peripheral biopsies for alpha-synuclein pathology using deep machine learning. *Alzheimeris and Dementia*, **2020**, 16, e047358	1.2	
341	Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test. *Journal of Medical Virology*, **2020**, 92, 1695-1698	19.7	67
340	Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells. *Aging*, **2020**, 12, 17694-17712	5.6	0
339	Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation. *Journal of Medical Internet Research*, **2020**, 22, e24018	7.6	82
338	Clinical Characteristics of Hospitalized Covid-19 Patients in New York City **2020**,		41
337	An inflammatory cytokine signature helps predict COVID-19 severity and death **2020**,		43
336	Gastrointestinal involvement attenuates COVID-19 severity and mortality **2020**,		19
335	COVID-19: Staging of a New Disease. *Cancer Cell*, **2020**, 38, 594-597	24.3	21
334	Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 3594-3596.e3	5.4	49

333	Molecular tracing of prostate cancer lethality. *Oncogene*, **2020**, 39, 7225-7238	9.2	2
332	Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. *Lancet Microbe, The*, **2020**, 1, e283-e289	22.2	86
331	Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in New York City. *BMJ Open*, **2020**, 10, e040736	3	21
330	SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Respiratory Medicine,the*, **2020**, 8, e70	35.1	280
329	Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*, **2020**, 370, 1227-1230	33.3	680
328	Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. *Journal of the American College of Cardiology*, **2020**, 76, 1815-1826	15.1	240
327	An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nature Medicine*, **2020**, 26, 1636-1643	50.5	895
326	Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. *Nature Medicine*, **2020**, 26, 1708-1713	50.5	290
325	Intragenic antagonistic roles of protein and circRNA in tumorigenesis. *Cell Research*, **2019**, 29, 628-640	24.7	70
324	exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. *Cell*, **2019**, 177, 463-477.e15	56.2	144
323	Artificial intelligence in neuropathology: deep learning-based assessment of tauopathy. *Laboratory Investigation*, **2019**, 99, 1019-1029	5.9	42
322	Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts. *Journal of Visualized Experiments*, **2019**,	1.6	1
321	Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. *Journal of Clinical Investigation*, **2019**, 129, 786-801	15.9	33
320	Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. *Journal of Clinical Investigation*, **2019**, 129, 215-222	15.9	11
319	Transformed bone marrow cells generate neoplasms of distinct histogenesis. a murine model of cancer transplantation. *Stem Cell Research*, **2019**, 41, 101637	1.6	
318	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. *Nature Genetics*, **2018**, 50, 206-218	36.3	153
317	Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 594-603	6.2	13
316	Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation. *Journal of Cardiac Failure*, **2018**, 24, 78-86	3.3	7

315	Integrated nanoscale deterministic lateral displacement arrays for separation of extracellular vesicles from clinically-relevant volumes of biological samples. *Lab on A Chip*, **2018**, 18, 3913-3925	7.2	79
314	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. *Nature Communications*, **2018**, 9, 3503	17.4	124
313	Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. *Journal of Trace Elements in Medicine and Biology*, **2018**, 48, 233-238	4.1	10
312	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. *Oncogene*, **2018**, 37, 5858-5872	9.2	15
311	The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. *Journal of Cell Biology*, **2017**, 216, 641-656	7.3	27
310	Nexgen Pathology: Predicting Clinical Course and Targeting Disease Causation **2017**, 1-9		
309	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. *Genes and Development*, **2017**, 31, 553-566	12.6	62
308	Reappraising hyalinizing clear cell carcinoma: A population-based study with molecular confirmation. *Head and Neck*, **2017**, 39, 503-511	4.2	17
307	PTEN counteracts FBXL2 to promote IP3R3- and Ca-mediated apoptosis limiting tumour growth. *Nature*, **2017**, 546, 554-558	50.4	139
306	Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. *Molecular Diagnosis and Therapy*, **2017**, 21, 115-123	4.5	6
305	Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel. *Journal of Visualized Experiments*, **2017**,	1.6	3
304	Targeting sarcoma tumor-initiating cells through differentiation therapy. *Stem Cell Research*, **2017**, 21, 117-123	1.6	8
303	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. *Nature*, **2017**, 547, 109-113	50.4	92
302	The role of GATA2 in lethal prostate cancer aggressiveness. *Nature Reviews Urology*, **2017**, 14, 38-48	5.5	49
301	Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. *American Journal of Pathology*, **2016**, 186, 3131-3145	5.8	17
300	H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. *Journal of Pediatric Urology*, **2016**, 12, 91.e1-7	1.5	6
299	Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs).. *Journal of Clinical Oncology*, **2016**, 34, 4538-4538	2.2	4
298	Protein Profiling of Bladder Urothelial Cell Carcinoma. *PLoS ONE*, **2016**, 11, e0161922	3.7	6

297	Immunopathologic Assessment of PTEN Expression. *Methods in Molecular Biology*, **2016**, 1388, 23-37	1.4	7
296	Function of microRNA activity by ActMiR in bladder cancer.. *Journal of Clinical Oncology*, **2016**, 34, 4531-4531	2.2	
295	Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2016**, 34, e16002-e16002	2.2	
294	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. *European Urology*, **2016**, 70, 771-775	10.2	42
293	The metabolic co-regulator PGC1β suppresses prostate cancer metastasis. *Nature Cell Biology*, **2016**, 18, 645-656	23.4	140
292	Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. *Methods*, **2015**, 77-78, 25-30	4.6	16
291	A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells. *Cancer Discovery*, **2015**, 5, 396-409	24.4	13
290	Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers. *Genes and Development*, **2015**, 29, 1631-48	12.6	69
289	Limited miR-17-92 overexpression drives hematologic malignancies. *Leukemia Research*, **2015**, 39, 335-41	2.7	17
288	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. *Nature Medicine*, **2015**, 21, 1182-9	50.5	139
287	PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. *Cancer Medicine*, **2015**, 4, 1258-71	4.8	30
286	Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria. *American Journal of Pathology*, **2015**, 185, 266-79	5.8	42
285	Np63 expression is a protective factor of progression in clinical high grade T1 bladder cancer. *Journal of Urology*, **2015**, 193, 1144-50	2.5	18
284	Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. *Journal of Visualized Experiments*, **2015**, 53182	1.6	33
283	MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. *Cancer Discovery*, **2015**, 5, 636-51	24.4	52
282	Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. *Cancer Discovery*, **2015**, 5, 550-63	24.4	18
281	A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. *Cancer Cell*, **2015**, 27, 223-39	24.3	94
280	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. *Nature Communications*, **2015**, 6, 6087	17.4	183

279	Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. *Oncoscience*, **2015**, 2, 607-14	0.8	17
278	Prostate cancer prognosis via integrative and co-localized glandular morphometry and immunofluorescent protein biomarker expression.. *Journal of Clinical Oncology*, **2015**, 33, 262-262	2.2	1
277	Characterization of molecular features of pediatric urothelial bladder carcinomas.. *Journal of Clinical Oncology*, **2015**, 33, 345-345	2.2	
276	Incorporation of advanced image analysis in novel post-prostatectomy systems pathology models as an approach to replace the clinical Gleason and provide robust risk stratification.. *Journal of Clinical Oncology*, **2015**, 33, e16134-e16134	2.2	
275	The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. *Genes and Development*, **2014**, 28, 765-82	12.6	52
274	Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers. *Expert Review of Molecular Diagnostics*, **2014**, 14, 1023-31	3.8	1
273	RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. *Cancer Discovery*, **2014**, 4, 318-33	24.4	65
272	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. *Nature Medicine*, **2014**, 20, 1130-7	50.5	269
271	Bladder cancers arise from distinct urothelial sub-populations. *Nature Cell Biology*, **2014**, 16, 982-91, 1-5	23.4	132
270	Isolation of cancer stem cells from human prostate cancer samples. *Journal of Visualized Experiments*, **2014**,	1.6	4
269	The microRNA 424/503 cluster reduces CDC25A expression during cell cycle arrest imposed by transforming growth factor □in mammary epithelial cells. *Molecular and Cellular Biology*, **2014**, 34, 4216-31	4.8	35
268	FBXW7 mutations in melanoma and a new therapeutic paradigm. *Journal of the National Cancer Institute*, **2014**, 106, dju107	9.7	63
267	Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers. *Current Opinion in Urology*, **2014**, 24, 303-10	2.8	7
266	Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. *Journal of the American Academy of Dermatology*, **2014**, 70, 1036-44	4.5	12
265	Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. *PLoS ONE*, **2014**, 9, e98786	3.7	33
264	Biomarkers for bladder cancer management: present and future. *American Journal of Clinical and Experimental Urology*, **2014**, 2, 1-14	1.6	34
263	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program.. *Journal of Clinical Oncology*, **2014**, 32, e16002-e16002	2.2	
262	□□□□N-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL. *Blood*, **2014**, 124, 487-487	2.2	

261	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program.. *Journal of Clinical Oncology*, **2014**, 32, 111-111	2.2	
260	Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. *Cancer Cell*, **2013**, 24, 766-76	24.3	174
259	A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. *American Journal of Pathology*, **2013**, 182, 1171-9	5.8	25
258	Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling. *American Journal of Pathology*, **2013**, 182, 2015-27	5.8	18
257	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. *Nature Genetics*, **2013**, 45, 747-55	36.3	121
256	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. *Nature Genetics*, **2013**, 45, 739-746	36.3	100
255	A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer. *Cancer*, **2012**, 118, 358-64	6.4	28
254	Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. *Cancer Cell*, **2012**, 22, 373-88	24.3	316
253	miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. *American Journal of Pathology*, **2012**, 180, 1808-15	5.8	126
252	CpG ODN, Toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model. *Journal of Surgical Research*, **2012**, 174, 284-90	2.5	13
251	A BAC-based transgenic mouse specifically expresses an inducible Cre in the urothelium. *PLoS ONE*, **2012**, 7, e35243	3.7	11
250	PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. *Clinical and Translational Oncology*, **2012**, 14, 197-206	3.6	15
249	A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer. *BJU International*, **2012**, 109, 207-13	5.6	5
248	Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery. *BJU International*, **2012**, 109, 40-5	5.6	6
247	Targeting nonclassical oncogenes for therapy in T-ALL. *Cancer Cell*, **2012**, 21, 459-72	24.3	79
246	Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression. *Genes and Cancer*, **2012**, 3, 599-603	2.9	4
245	Perioperative polyphenon E, a green tea extract, does not affect the wound complication rate in mice after sham laparotomy yet has an inhibitory effect on wound healing. *Surgical Innovation*, **2012**, 19, 399-406	2	1
244	Preclinical analysis of the □secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. *Molecular Cancer Therapeutics*, **2012**, 11, 1565-75	6.1	89

243	Translocation renal cell carcinomas in adults: a single-institution experience. *American Journal of Surgical Pathology*, **2012**, 36, 654-62	6.7	79
242	PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. *Journal of Clinical Investigation*, **2012**, 122, 886-98	15.9	54
241	Therapeutic Utility of PI3Kδ Inhibition in Leukemogenesis and Tumor Cell Survival. *Blood*, **2012**, 120, 1492-1492	21.4	0
240	An Oncogenic Metabolic Switch Mediates Resistance to NOTCH1 Inhibition in T-ALL. *Blood*, **2012**, 120, 285-285	2.2	
239	Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. *American Journal of Pathology*, **2011**, 178, 1350-60	5.8	98
238	KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. *American Journal of Pathology*, **2011**, 179, 540-6	5.8	39
237	Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. *Cancer Cell*, **2011**, 20, 173-86	24.3	131
236	Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis. *Clinical and Translational Oncology*, **2011**, 13, 194-203	3.6	11
235	Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. *Cancer Research*, **2011**, 71, 716-24	10.1	44
234	Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. *Cancer Research*, **2011**, 71, 964-75	10.1	54
233	A Role for PML in Innate Immunity. *Genes and Cancer*, **2011**, 2, 10-9	2.9	32
232	Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth. *Cancer Research*, **2011**, 71, 725-35	10.1	16
231	Personalized approach to prostate cancer prognosis. *Archivos Espanoles De Urologia*, **2011**, 64, 783-91	0.4	1
230	Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. *Nature*, **2010**, 464, 374-9	50.4	315
229	PHF6 mutations in T-cell acute lymphoblastic leukemia. *Nature Genetics*, **2010**, 42, 338-42	36.3	231
228	The TLX1 oncogene drives aneuploidy in T cell transformation. *Nature Medicine*, **2010**, 16, 1321-7	50.5	123
227	Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. *BJU International*, **2010**, 105, 462-7	5.6	53
226	Integrative genome comparison of primary and metastatic melanomas. *PLoS ONE*, **2010**, 5, e10770	3.7	129

225	Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. *Carcinogenesis*, **2010**, 31, 1264-71	4.6	33
224	Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited. *Cancer Research*, **2010**, 70, 8179-86	10.1	49
223	Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes. *Genes and Cancer*, **2010**, 1, 115-24	2.9	61
222	Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. *Clinical Cancer Research*, **2010**, 16, 240-8	12.9	122
221	Molecular pathways of urothelial development and bladder tumorigenesis. *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 401-8	2.8	189
220	Galectin-3 expression is associated with bladder cancer progression and clinical outcome. *Tumor Biology*, **2010**, 31, 277-85	2.9	54
219	Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. *International Journal of Cancer*, **2010**, 127, 2169-82	7.5	35
218	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2010**, 116, 471-471	2.2	
217	Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. *Clinical Cancer Research*, **2009**, 15, 3842-9	12.9	28
216	Inactivation of p53 and Pten promotes invasive bladder cancer. *Genes and Development*, **2009**, 23, 675-80	12.6	221
215	3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. *Cancer Research*, **2009**, 69, 6299-306	10.1	106
214	Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. *Cancer Prevention Research*, **2009**, 2, 1008-14	3.2	63
213	Comparison of models to predict clinical failure after radical prostatectomy. *Cancer*, **2009**, 115, 303-10	6.4	14
212	Systems pathology: a paradigm shift in the practice of diagnostic and predictive pathology. *Cancer*, **2009**, 115, 3078-84	6.4	21
211	Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. *Nature Genetics*, **2009**, 41, 619-24	36.3	526
210	Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. *Nature Medicine*, **2009**, 15, 50-8	50.5	373
209	Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer. *Radiology*, **2009**, 250, 803-12	20.5	23
208	Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?. *Cancer Letters*, **2009**, 279, 126-36	9.9	104

207	Cyfip1 is a putative invasion suppressor in epithelial cancers. *Cell*, **2009**, 137, 1047-61	56.2	63
206	MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. *Expert Review of Anticancer Therapy*, **2009**, 9, 1135-44	3.5	106
205	miR-19 is a key oncogenic component of mir-17-92. *Genes and Development*, **2009**, 23, 2839-49	12.6	478
204	Differential requirement of mTOR in postmitotic tissues and tumorigenesis. *Science Signaling*, **2009**, 2, ra2	8.8	55
203	Personalized prediction of tumor response and cancer progression on prostate needle biopsy. *Journal of Urology*, **2009**, 182, 125-32	2.5	43
202	The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.. *Blood* , **2009**, 114, 142-142	2.2	7
201	Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage. *Molecular Cell*, **2008**, 31, 21-32	17.6	53
200	A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. *American Journal of Pathology*, **2008**, 172, 1069-80	5.8	58
199	Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. *Cancer Research*, **2008**, 68, 2241-9	10.1	135
198	p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. *Journal of Cell Science*, **2008**, 121, 4098-105	5.3	28
197	Identification of PMF1 methylation in association with bladder cancer progression. *Clinical Cancer Research*, **2008**, 14, 8236-43	12.9	34
196	Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. *Journal of Clinical Oncology*, **2008**, 26, 3923-9	2.2	74
195	Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. *Genes and Development*, **2008**, 22, 2172-7	12.6	98
194	A context dependent role for Wnt signaling in tumorigenesis and stem cells. *Cell Cycle*, **2008**, 7, 720-4	4.7	18
193	DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. *Genes and Development*, **2008**, 22, 1439-44	12.6	141
192	TREK-1 is a novel molecular target in prostate cancer. *Cancer Research*, **2008**, 68, 1197-203	10.1	83
191	Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. *Journal of Clinical Investigation*, **2008**, 118, 3051-64	15.9	290
190	Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL. *Blood*, **2008**, 112, 298-298	2.2	2

189	Tissue-specific and reversible RNA interference in transgenic mice. *Nature Genetics*, **2007**, 39, 914-21	36.3	155
188	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. *Nature Medicine*, **2007**, 13, 748-53	50.5	243
187	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. *Nature Medicine*, **2007**, 13, 1203-10	50.5	708
186	Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1). *EMBO Journal*, **2007**, 26, 4683-93	13	46
185	Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature*, **2007**, 445, 656-60	50.4	1786
184	Prognostic significance of p27Kip1 expression in bladder cancer. *BJU International*, **2007**, 100, 259-63	5.6	31
183	Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. *Cancer Cell*, **2007**, 11, 9-23	24.3	488
182	Molecular alterations associated with bladder cancer progression. *Seminars in Oncology*, **2007**, 34, 75-84	5.5	52
181	Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 16633-8	11.5	207
180	Role of the chromobox protein CBX7 in lymphomagenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 5389-94	11.5	125
179	Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. *Cancer Research*, **2007**, 67, 7106-12	10.1	122
178	Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. *Clinical Cancer Research*, **2007**, 13, 4511-8	12.9	23
177	NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. *Cell*, **2007**, 128, 129-39	56.2	524
176	Ubiquitination regulates PTEN nuclear import and tumor suppression. *Cell*, **2007**, 128, 141-56	56.2	572
175	Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression. *American Journal of Pathology*, **2007**, 171, 1650-8	5.8	28
174	Technology insight: will systems pathology replace the pathologist?. *Nature Reviews Urology*, **2007**, 4, 39-45		26
173	A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. *Clinical Cancer Research*, **2007**, 13, 3215-20	12.9	51
172	Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. *Journal of Clinical Investigation*, **2007**, 117, 314-25	15.9	89

171	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. *Journal of Clinical Investigation*, **2007**, 117, 3248-57	15.9	150
170	Improved prediction of prostate cancer recurrence through systems pathology. *Journal of Clinical Investigation*, **2007**, 117, 1876-83	15.9	91
169	Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL.. *Blood*, **2007**, 110, 151-151	2.2	1
168	Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas--a tissue microarray study. *Anticancer Research*, **2007**, 27, 283-8	2.3	27
167	Amplification of CDK4 and MDM2 in malignant melanoma. *Genes Chromosomes and Cancer*, **2006**, 45, 447-54	5	119
166	Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. *Cancer Research*, **2006**, 66, 7639-46	10.1	94
165	Profiling bladder cancer using targeted antibody arrays. *American Journal of Pathology*, **2006**, 168, 93-103	5.8	148
164	Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. *Cell*, **2006**, 125, 1253-67	56.2	903
163	Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. *Cell*, **2006**, 125, 1269-81	56.2	352
162	Identification of a tumour suppressor network opposing nuclear Akt function. *Nature*, **2006**, 441, 523-7	50.4	332
161	PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. *Nature*, **2006**, 442, 779-85	50.4	320
160	Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. *Journal of Clinical Oncology*, **2006**, 24, 778-89	2.2	455
159	Differential exoprotease activities confer tumor-specific serum peptidome patterns. *Journal of Clinical Investigation*, **2006**, 116, 271-84	15.9	593
158	Autocrine PDGFR signaling promotes mammary cancer metastasis. *Journal of Clinical Investigation*, **2006**, 116, 1561-70	15.9	254
157	Altered expression of DNA double-strand repair genes Ku70 and Ku80 in carcinomas of the oral cavity. *Anticancer Research*, **2006**, 26, 2101-5	2.3	10
156	Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours. *Anticancer Research*, **2006**, 26, 2107-12	2.3	11
155	Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. *Oncology Reports*, **2006**, 16, 807-10	3.5	14
154	Alterations of the retinoblastoma and p16 pathway correlate with promoter methylation in malignant fibrous histiocytomas. *Anticancer Research*, **2006**, 26, 3461-5	2.3	1

153	Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. *Nature*, **2005**, 433, 278-85	50.4	418
152	A novel multiplexing, polymerase chain reaction-based assay for the analysis of chromosome 18q status in colorectal cancer. *Journal of Molecular Diagnostics*, **2005**, 7, 478-85	5.1	5
151	A novel logistic model based on clinicopathological features predicts microsatellite instability in colorectal carcinomas. *Diagnostic Molecular Pathology*, **2005**, 14, 213-23		10
150	Gene expression profiling in single cells within tissue. *Nature Methods*, **2005**, 2, 663-5	21.6	49
149	A microRNA polycistron as a potential human oncogene. *Nature*, **2005**, 435, 828-33	50.4	3084
148	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. *Nature*, **2005**, 436, 807-11	50.4	379
147	Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature*, **2005**, 436, 725-30	50.4	1535
146	A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. *Clinical Cancer Research*, **2005**, 11, 3836-45	12.9	99
145	Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. *Genes and Development*, **2005**, 19, 1779-86	12.6	93
144	Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. *Clinical Cancer Research*, **2005**, 11, 3296-302	12.9	57
143	p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. *Cancer Research*, **2005** , 65, 2186-92	10.1	36
142	Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. *Clinical Cancer Research*, **2005**, 11, 1999-2007	12.9	174
141	Cytokeratin expression correlates with aneuploidy in cytological specimens of melanoma metastases. *Anticancer Research*, **2005**, 25, 2789-92	2.3	5
140	Relationship of nm23 expression to proliferation and prognosis in malignant melanomas of the oral cavity. *In Vivo*, **2005**, 19, 1093-6	2.3	5
139	Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. *Clinical Cancer Research*, **2004**, 10, 1835-42	12.9	30
138	Loss of the tumor suppressor PML in human cancers of multiple histologic origins. *Journal of the National Cancer Institute*, **2004**, 96, 269-79	9.7	277
137	Role of Dok-1 and Dok-2 in leukemia suppression. *Journal of Experimental Medicine*, **2004**, 200, 1689-95	16.6	75
136	High-resolution characterization of the pancreatic adenocarcinoma genome. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 9067-72	11.5	228

135	Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. *Nature Genetics*, **2004**, 36, 906-12	36.3	66
134	The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. *Nature Medicine*, **2004**, 10, 484-6	50.5	494
133	Analysis of adenomatous polyposis coli gene expression, APC locus-microsatellite instability and APC promoter methylation in the progression of melanocytic tumours. *Modern Pathology*, **2004**, 17, 1539-44	9.8	14
132	Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. *Nature*, **2004**, 428, 332-7	50.4	830
131	Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. *Nature*, **2004**, 430, 797-802	50.4	457
130	Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo. *Methods in Enzymology*, **2004**, 376, 199-205	1.7	15
129	Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. *Diagnostic Molecular Pathology*, **2004**, 13, 217-23		33
128	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. *Blood*, **2004**, 103, 2358-62	9.2	57
127	Critical Role of Dok-1 and Dok-2 in Leukemia Suppression.. *Blood*, **2004**, 104, 2951-2951	2.2	
126	Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases. *Anticancer Research*, **2004**, 24, 981-6	2.3	11
125	Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. *Molecular Cancer Therapeutics*, **2004**, 3, 921-32	6.1	52
124	Cytokeratin positivity in paraffin-embedded malignant melanomas: comparative study of KL1, A4 and Lu5 antibodies. *Anticancer Research*, **2004**, 24, 3203-7	2.3	12
123	Analysis of the p53-hMDM2-p21 (WAF1/CIP1) Cell Cycle Regulation Pathway in Malignant Fibrous Histiocytomas. *Cancer Genomics and Proteomics*, **2004**, 1, 419-426	3.3	
122	Quantitative Analysis of Ku70 and Ku80 mRNA Gene Expression in Melanoma Brain Metastases. Correlation with Immunohistochemistry and Hybridization. *Cancer Genomics and Proteomics*, **2004**, 1, 225-230	3.3	1
121	MDM2 and Prognosis. *Molecular Cancer Research*, **2004**, 2, 1-8	6.6	153
120	Comparison of gene expression profiles in laser-microdissected, nonembedded, and OCT-embedded tumor samples by oligonucleotide microarray analysis. *Clinical Chemistry*, **2003**, 49, 2096-100	5.5	16
119	Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. *Journal of Clinical Oncology*, **2003**, 21, 1775-81	2.2	152
118	Pten dose dictates cancer progression in the prostate. *PLoS Biology*, **2003**, 1, E59	9.7	537

117	p27 as a target for cancer therapeutics. *Cancer Cell*, **2003**, 3, 111-5	24.3	137
116	A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell*, **2003**, 3, 537-49	24.3	2050
115	p27 deficiency desensitizes Rb-/- cells to signals that trigger apoptosis during pituitary tumor development. *Oncogene*, **2003**, 22, 361-9	9.2	26
114	Oncogenes in melanoma. *Oncogene*, **2003**, 22, 3087-91	9.2	88
113	Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome. *Oncogene*, **2003**, 22, 5298-305	9.2	42
112	Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes. *Laboratory Investigation*, **2003**, 83, 507-17	5.9	22
111	Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. *Modern Pathology*, **2003**, 16, 742-51	9.8	83
110	An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. *Nature Genetics*, **2003**, 33, 396-400	36.3	320
109	Tumor response to radiotherapy regulated by endothelial cell apoptosis. *Science*, **2003**, 300, 1155-9	33.3	1260
108	Gene discovery in bladder cancer progression using cDNA microarrays. *American Journal of Pathology*, **2003**, 163, 505-16	5.8	154
107	Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. *American Journal of Pathology*, **2003**, 163, 691-700	5.8	185
106	Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. *American Journal of Pathology*, **2003**, 162, 609-17	5.8	132
105	Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. *Science*, **2003**, 299, 259-62	33.3	340
104	p73alpha regulation by Chk1 in response to DNA damage. *Molecular and Cellular Biology*, **2003**, 23, 8161-78	4.8	72
103	Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. *Journal of Clinical Oncology*, **2003**, 21, 406-12	2.2	73
102	Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. *Cancer Research*, **2003**, 63, 179-85	10.1	26
101	Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. *Cancer Research*, **2003**, 63, 2872-80	10.1	178
100	Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. *Clinical Cancer Research*, **2003**, 9, 2613-9	12.9	50

99	Tumor promotion by Mdm2 splice variants unable to bind p53. *Cancer Research*, **2003**, 63, 5703-6	10.1	52
98	Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. *Cancer Research*, **2003**, 63, 7799-806	10.1	144
97	p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. *Clinical Cancer Research*, **2003**, 9, 5642-51	12.9	48
96	Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. *Journal of Clinical Oncology*, **2002**, 20, 2980-7	2.2	56
95	Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression. *Modern Pathology*, **2002**, 15, 426-33	9.8	16
94	HDM2 protein overexpression and prognosis in primary malignant melanoma. *Journal of the National Cancer Institute*, **2002**, 94, 1803-6	9.7	63
93	The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. *American Journal of Pathology*, **2002**, 160, 1215-21	5.8	93
92	Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. *American Journal of Pathology*, **2002**, 161, 365-71	5.8	80
91	Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. *American Journal of Pathology*, **2002**, 160, 175-83	5.8	66
90	Loss of p63 expression is associated with tumor progression in bladder cancer. *American Journal of Pathology*, **2002**, 161, 1199-206	5.8	215
89	The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. *Immunity*, **2002**, 17, 437-49	32.3	163
88	Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. *Clinical Cancer Research*, **2002**, 8, 171-9	12.9	92
87	p63 expression profiles in human normal and tumor tissues. *Clinical Cancer Research*, **2002**, 8, 494-501	12.9	347
86	Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. *Clinical Cancer Research*, **2002**, 8, 679-83	12.9	117
85	Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. *Clinical Cancer Research*, **2002**, 8, 782-7	12.9	48
84	17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. *Clinical Cancer Research*, **2002**, 8, 986-93	12.9	304
83	Decreased expression of Ku70/Ku80 proteins in malignant melanomas of the oral cavity. *Anticancer Research*, **2002**, 22, 193-6	2.3	5
82	Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. *Clinical Cancer Research*, **2002**, 8, 3226-31	12.9	69

81	Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas. *International Journal of Molecular Medicine*, **2002**, 10, 707-11	4.4	11
80	Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. *Cancer Research*, **2002**, 62, 6973-80	10.1	123
79	Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. *Clinical Cancer Research*, **2002**, 8, 3841-9	12.9	42
78	High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. *Cancer*, **2001**, 92, 869-74	6.4	72
77	Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. *International Journal of Cancer*, **2001**, 95, 223-7	7.5	85
76	Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma. *Breast Cancer Research and Treatment*, **2001**, 65, 225-32	4.4	20
75	Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. *Laboratory Investigation*, **2001**, 81, 895-903	5.9	55
74	Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. *Laboratory Investigation*, **2001**, 81, 1331-8	5.9	217
73	Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. *Nature Genetics*, **2001**, 27, 222-4	36.3	409
72	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. *Nature*, **2001**, 409, 207-11	50.4	831
71	Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. *Cancer Genetics and Cytogenetics*, **2001**, 125, 131-8		17
70	Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. *Modern Pathology*, **2001**, 14, 1270-6	9.8	46
69	Mzf1 controls cell proliferation and tumorigenesis. *Genes and Development*, **2001**, 15, 1625-30	12.6	107
68	Applications of molecular diagnostics: solid tumor genetics can determine clinical treatment protocols. *Modern Pathology*, **2001**, 14, 254-7	9.8	10
67	Role of promyelocytic leukemia (PML) protein in tumor suppression. *Journal of Experimental Medicine*, **2001**, 193, 521-29	16.6	128
66	Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. *American Journal of Pathology*, **2001**, 158, 1245-51	5.8	323
65	Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. *Science*, **2001**, 293, 293-7	33.3	1035
64	Ronald A. DeLellis, M.D., recipient of the 1999 Fred W. Stewart Award. *American Journal of Surgical Pathology*, **2000**, 24, 295	6.7	

63	Evaluation of the Performance of a p53 Sequencing Microarray Chip Using 140 Previously Sequenced Bladder Tumor Samples. *Clinical Chemistry*, **2000**, 46, 1555-1561	5.5	80
62	Genetic and molecular markers of urothelial premalignancy and malignancy. *Scandinavian Journal of Urology and Nephrology*, **2000**, 82-93		49
61	Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications. *American Journal of Pathology*, **2000**, 156, 977-83	5.8	75
60	Apoptosis, proliferation, and p27 expression during vessel wall healing: time course study in a mouse model of transluminal femoral artery injury. *Journal of Vascular Surgery*, **2000**, 32, 1022-9	3.5	21
59	Mutation of cell cycle regulators and their impact on superficial bladder cancer. *Urologic Clinics of North America*, **2000**, 27, 83-102, ix	2.9	33
58	Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model. *Atherosclerosis*, **2000**, 153, 315-22	3.1	45
57	DNA Microchips: Technical and Practical Considerations. *Current Organic Chemistry*, **2000**, 4, 945-971	1.7	27
56	Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. *Journal of the National Cancer Institute*, **1999**, 91, 874-81	9.7	46
55	At the crossroads of inflammation and tumorigenesis. *Journal of Experimental Medicine*, **1999**, 190, 1367-70	16.6	109
54	Essential role for oncogenic Ras in tumour maintenance. *Nature*, **1999**, 400, 468-72	50.4	777
53	Impaired Fas response and autoimmunity in Pten+/- mice. *Science*, **1999**, 285, 2122-5	33.3	457
52	Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. *American Journal of Pathology*, **1999**, 155, 105-13	5.8	106
51	Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. *American Journal of Pathology*, **1999**, 155, 1855-60	5.8	147
50	Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. *American Journal of Pathology*, **1999**, 155, 1885-91	5.8	100
49	Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. *Nature*, **1998**, 393, 483-7	50.4	180
48	Pten is essential for embryonic development and tumour suppression. *Nature Genetics*, **1998**, 19, 348-55	36.3	1298
47	Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. *Cancer*, **1998**, 83, 490-7	6.4	71
46	Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors. *International Journal of Cancer*, **1998**, 75, 819-24	7.5	22

45	Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. *Molecular Cell*, **1998**, 2, 1-8	17.6	205
44	The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell*, **1998**, 92, 713-23	56.2	1316
43	Role of PML in cell growth and the retinoic acid pathway. *Science*, **1998**, 279, 1547-51	33.3	445
42	Expression of Granulocyte-Macrophage Colony-Stimulating Factor Receptors in Human Prostate Cancer. *Blood*, **1998**, 91, 1037-1043	2.2	41
41	Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors **1998**, 75, 819		2
40	Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. *Journal of Experimental Medicine*, **1997**, 186, 1831-41	16.6	381
39	Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. *Journal of Experimental Medicine*, **1997**, 186, 921-9	16.6	232
38	Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer. *World Journal of Urology*, **1997**, 15, 112-9	4	13
37	Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **1997**, 430, 125-30	5.1	34
36	Genetic studies and molecular markers of bladder cancer. *Journal of Surgical Oncology*, **1997**, 13, 319-27		38
35	Chromosome 16 in primary prostate cancer: a microsatellite analysis. *International Journal of Cancer* , **1997**, 71, 580-4	7.5	16
34	Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. *International Journal of Cancer*, **1997**, 73, 42-9	7.5	224
33	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. *International Journal of Cancer*, **1997**, 73, 50-6	7.5	177
32	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens **1997**, 73, 50		2
31	Genetic studies and molecular markers of bladder cancer **1997**, 13, 319		1
30	Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. *Cell*, **1996**, 86, 189-99	56.2	710
29	Role of the INK4a locus in tumor suppression and cell mortality. *Cell*, **1996**, 85, 27-37	56.2	1396
28	Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. *International Journal of Cancer*, **1996**, 69, 110-3	7.5	27

27	Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines. *International Journal of Cancer*, **1996**, 68, 514-9	7.5	13
26	Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors. *European Journal of Nuclear Medicine and Molecular Imaging*, **1995**, 22, 419-26		18
25	A case-series study of p53 nuclear overexpression in early-stage stomach cancer. *Annals of the New York Academy of Sciences*, **1995**, 768, 269-71	6.5	1
24	p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. *International Journal of Cancer*, **1994**, 56, 347-53	7.5	197
23	Bladder cancer: advances in biology and treatment. *Critical Reviews in Oncology/Hematology*, **1994**, 16, 33-70	7	7
22	Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49. *Cancer Investigation*, **1994**, 12, 551-8	2.1	6
21	Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. *Journal of Urology*, **1994**, 152, 2120-4	2.5	77
20	Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma. *Cancer Investigation*, **1994**, 12, 20-5	2.1	5
19	Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. *American Journal of Surgical Pathology*, **1994**, 18, 979-91	6.7	116
18	P-glycoprotein expression in brain tumors. *Journal of Neuro-Oncology*, **1992**, 14, 37-43	4.8	57
17	Cell surface differentiation antigens of normal urothelium and bladder tumors. *Journal of Surgical Oncology*, **1992**, 8, 293-9		6
16	Expression of blood group antigens in bladder cancer: current concepts. *Journal of Surgical Oncology*, **1992**, 8, 308-15		13
15	Blood group antigens in normal and neoplastic urothelium. *Journal of Cellular Biochemistry*, **1992**, 16I, 50-5	4.7	12
14	Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. *Cancer*, **1992**, 70, 633-8	6.4	74
13	The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. *Cell*, **1991**, 66, 173-83	56.2	495
12	The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. *Cell*, **1991**, 66, 395-403	56.2	813
11	Cell-surface antigens of human lung tumors detected by mouse monoclonal antibodies: definition of blood-group- and non-blood-group-related antigenic systems. *International Journal of Cancer*, **1990**, 46, 1007-13	7.5	14
10	Altered expression of the retinoblastoma gene product in human sarcomas. *New England Journal of Medicine*, **1990**, 323, 1457-62	59.2	192

9	Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. *New England Journal of Medicine*, **1989**, 320, 773-7	59.2	200
8	Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. *American Journal of Dermatopathology*, **1989**, 11, 577-81	0.9	15
7	Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. *Journal of Investigative Dermatology*, **1988**, 90, 459-66	4.3	72
6	HIV antigen in the brains of patients with the AIDS dementia complex. *Annals of Neurology*, **1987**, 21, 490-6	9.4	267
5	Changes in cell surface glycoprotein expression during differentiation of human keratinocytes. *Journal of Investigative Dermatology*, **1987**, 89, 500-6	4.3	53
4	Immunohistologic expression of blood-group antigens in normal human gastrointestinal tract and colonic carcinoma. *International Journal of Cancer*, **1986**, 37, 667-76	7.5	58
3	Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. *International Journal of Cancer*, **1985**, 35, 469-75	7.5	39
2	Immunohistochemical localization of La nuclear antigen in brain. Selective concentration of the La protein in neuronal nucleoli. *Journal of Neuroimmunology*, **1985**, 9, 307-19	3.5	11
1	Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody. *Brain Research*, **1984**, 324, 190-4	3.7	39